Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

FDA working with FTC on switch ads prior to approval -- FTC's Peeler says.

This article was originally published in The Tan Sheet

Executive Summary

FDA WORKING WITH FTC ON Rx-TO-OTC SWITCHES PRIOR TO APPROVAL, Federal Trade Commission Division of Advertising Practices Associate Director Lee Peeler said at a Sept. 7 Food & Drug Law Institute meeting in Washington, D.C. He noted that FDA "has already initiated a series of steps to keep us informed about the advertising issues that are likely to arise after [a] switch" and that the agency is keeping FTC informed as to which switch products are in the pipeline.
Advertisement

Topics

Advertisement
UsernamePublicRestriction

Register

PS084267

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel